Alkermes plc (ALKS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$46.10-1.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ALKS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 1,667.7 | 1,475.9 | 1,557.6 | 1,663.4 | 1,111.8 | 1,173.8 | 1,038.8 | 1,170.9 | 1,094.3 | 903.4 | 745.7 | 628.3 | 618.8 | 575.5 | 575.5 | 390.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 903.4 | 745.7 | 628.3 | 618.8 | 575.5 | 575.5 | 390.0 |
| Cost of Revenues | 257.5 | 196.5 | 245.3 | 253.0 | 218.1 | 197.3 | 178.3 | 180.4 | 176.4 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 841.2 | 701.5 | 645.2 | 689.8 | 590.8 | 549.6 | 538.8 | 599.4 | 526.4 | 421.6 | 374.1 | 311.6 | 199.9 | 125.8 | 125.8 | 137.6 |
| R&D Expenses | 391.0 | 324.0 | 245.3 | 270.8 | 272.7 | 290.9 | 394.6 | 512.8 | 425.4 | 412.9 | 387.1 | 344.4 | 272.0 | 140.0 | 140.0 | 141.9 |
| Operating Income | 117.3 | 254.0 | 420.6 | 414.1 | (6.1) | 97.7 | (112.4) | (175.5) | (99.1) | (147.9) | (208.7) | (224.3) | (87.1) | 81.8 | 81.8 | (88.3) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 12.3 | 22.6 | 23.0 | 13.0 | 11.2 | 8.7 | 13.6 | 15.4 | 12.0 | 14.9 | 13.2 | 13.4 | 49.0 | 49.0 | 28.1 |
| Interest & Investment Income | 38.0 | 45.3 | 42.5 | 30.9 | 7.6 | 2.4 | 7.0 | 14.0 | 9.2 | 4.6 | 3.8 | 3.3 | 2.0 | 0.8 | 0.8 | 1.5 |
| Net Interest Expenses | — | — | — | (7.8) | 5.4 | 8.8 | 1.7 | (0.4) | 6.2 | 7.4 | 11.1 | 9.9 | 11.5 | 48.2 | 48.2 | 26.6 |
| Other Non-Operating Income / Expenses | (19.9) | 37.5 | 23.1 | 7.4 | (25.0) | (10.0) | 15.9 | (21.6) | (27.8) | 4.6 | (5.7) | 0.3 | 73.1 | (46.4) | (46.4) | (26.1) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | 3.3 | 3.3 | 3.3 | — |
| EBT, Incl. Unusual Items | 97.3 | 291.5 | 443.8 | 421.5 | (31.1) | 87.7 | (96.5) | (197.1) | (127.0) | (143.3) | (214.4) | (224.0) | (14.0) | 35.4 | 35.4 | (114.4) |
| Income Tax Expense | 31.2 | 49.8 | 71.6 | (97.6) | 2.0 | 11.3 | 14.3 | (0.4) | 12.3 | 14.7 | (5.9) | 3.2 | 16.0 | 10.5 | 10.5 | (0.7) |
| Net Income | ||||||||||||||||
| Net Income | 66.2 | 241.7 | 367.1 | 355.8 | (158.3) | (48.2) | (110.9) | (196.6) | (139.3) | (157.9) | (208.4) | (227.2) | (30.1) | 25.0 | 25.0 | (113.7) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.40 | 1.47 | 2.22 | 2.14 | (0.97) | (0.30) | (0.70) | — | — | — | — | (1.52) | (0.21) | 0.19 | 0.19 | (0.99) |
| Diluted EPS | 0.38 | 1.43 | 2.17 | 2.10 | (0.97) | (0.29) | (0.70) | — | — | — | — | (1.52) | (0.21) | 0.18 | 0.18 | (0.99) |
| Revenue per Share | 9.61 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 167.0 | 164.7 | 165.4 | 166.2 | 163.7 | 160.9 | 158.8 | — | — | — | — | 149.2 | 145.3 | 131.7 | 131.7 | 114.7 |
| Diluted Weighted Avg Shares | 173.5 | 168.7 | 169.2 | 169.7 | 163.7 | 164.8 | 158.8 | — | — | — | — | 149.2 | 145.3 | 137.1 | 137.1 | 114.7 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 281.1 | 449.2 | 489.0 | 71.8 | 176.4 | (30.6) | (95.1) | 4.5 | (49.4) | (114.4) | (138.7) | 10.9 | 155.6 | 155.6 | (40.4) |
| EBIT | 117.3 | 254.0 | 420.6 | 414.1 | (6.1) | 97.7 | (112.4) | (175.5) | (99.1) | (147.9) | (208.7) | (224.3) | (87.1) | 81.8 | 81.8 | (88.3) |
| Effective Tax Rate | 32.1% | — | — | -23.2% | -6.5% | 12.9% | -14.8% | 0.2% | -9.7% | -10.2% | 2.8% | -1.4% | -114.3% | 29.5% | 29.5% | 0.6% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.